AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
MiNK Therapeutics, Inc.
Video analysis: INKT
All videosNo video analysis for this stock yet. Request one from our team.
News: INKT
MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript
MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript
MiNK Therapeutics Q2 Earnings Call Highlights
MiNK Therapeutics NASDAQ: INKT said it initiated dosing in a randomized Phase II trial of its allogeneic invariant natural killer T-cell therapy, agenT-797, for patients with acute lung injury and acute respiratory distress syndrome, or ARDS, during the second quarter of 2026.
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune disorders, today reported financial results for the second quarter ended June 30, 2026, and provided an update on the clinical advancement of its lead candidate, agenT-797.
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026. The Company will host a conference call and webcast at 8:30 AM ET that morning to review financial results and provide a corporate update focused on the clinical advancement of agenT-797, MiNK's off-the-shelf allogeneic iNKT cell therapy, in acute lung injury.
Here's Why You Should Add INKT Stock to Your Portfolio Now
MiNK advances agenT-797 across respiratory, oncology and immune disease studies while expanding its next-generation engineered iNKT pipeline.
